PMC:7275137 / 14594-14944 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T42","span":{"begin":193,"end":201},"obj":"Disease"}],"attributes":[{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"vention data were analysed on 20th May 2020. Both observational and interventional trials were included in the table.\n\n3 Antibiotics\nInitial reports showed that more than 90% of patients with COVID-19 received antibiotics [24]; however, reports on how patient outcome depends on the use of different antibiotics are scarce. Several groups of antibio"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T91","span":{"begin":211,"end":222},"obj":"Chemical"},{"id":"T92","span":{"begin":301,"end":312},"obj":"Chemical"}],"attributes":[{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A92","pred":"chebi_id","subj":"T92","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"}],"text":"vention data were analysed on 20th May 2020. Both observational and interventional trials were included in the table.\n\n3 Antibiotics\nInitial reports showed that more than 90% of patients with COVID-19 received antibiotics [24]; however, reports on how patient outcome depends on the use of different antibiotics are scarce. Several groups of antibio"}

{"project":"LitCovid-sentences","denotations":[{"id":"T72","span":{"begin":45,"end":117},"obj":"Sentence"},{"id":"T73","span":{"begin":119,"end":133},"obj":"Sentence"},{"id":"T74","span":{"begin":134,"end":324},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"vention data were analysed on 20th May 2020. Both observational and interventional trials were included in the table.\n\n3 Antibiotics\nInitial reports showed that more than 90% of patients with COVID-19 received antibiotics [24]; however, reports on how patient outcome depends on the use of different antibiotics are scarce. Several groups of antibio"}

{"project":"LitCovid-PubTator","denotations":[{"id":"272","span":{"begin":179,"end":187},"obj":"Species"},{"id":"273","span":{"begin":253,"end":260},"obj":"Species"},{"id":"300","span":{"begin":193,"end":201},"obj":"Disease"}],"attributes":[{"id":"A272","pred":"tao:has_database_id","subj":"272","obj":"Tax:9606"},{"id":"A273","pred":"tao:has_database_id","subj":"273","obj":"Tax:9606"},{"id":"A300","pred":"tao:has_database_id","subj":"300","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"vention data were analysed on 20th May 2020. Both observational and interventional trials were included in the table.\n\n3 Antibiotics\nInitial reports showed that more than 90% of patients with COVID-19 received antibiotics [24]; however, reports on how patient outcome depends on the use of different antibiotics are scarce. Several groups of antibio"}